Original articleAlimentary tractStatin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases
Section snippets
Study Population
The population for this study consisted of a cohort of patients with CD or UC receiving care at 1 of 2 referral hospitals serving the Greater Boston metropolitan area. The development of this cohort has been described previously.27, 28, 29, 30 We identified all eligible patients with at least 1 International Classification of Diseases, 9th revision, clinical modification (ICD-9-CM) code for CD (555.x) or UC (556.x). By using a combination of ICD-9-CM codes for disease complications and
Results
Our study consisted of 11,001 patients with IBD among whom 1376 (12.5%) received 1 or more prescriptions for a statin (Table 1). Statin users were likely to be older, male, and white compared with nonusers. They were also more likely to have UC (62% vs 49%), although being less likely to require immunomodulator or anti-TNF biologic therapy use when compared with nonusers. Statin use also was associated with lower rates of surgery (8% vs 13%) and hospitalization (28% vs 31%) (P < .05 for both).
Discussion
Colorectal cancer is an important cause of morbidity and mortality in patients with inflammatory bowel diseases.1, 2, 3, 4, 5, 6 The efficacy of chemopreventives in reducing this risk has been weak and inconsistent, limited by the quality of data, much of which are from small cohorts or inadequately adjust for confounding disease-related factors.5, 6, 34 In this study, we used a large cohort of IBD patients with a long follow-up period to show a strong and robust inverse association between use
References (51)
Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis
Gastroenterol Clin North Am
(2006)- et al.
Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I)
J Crohns Colitis
(2014) - et al.
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota
Gastroenterology
(2006) - et al.
Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years
Gastroenterology
(2012) - et al.
Field cancerization in the intestinal epithelium of patients with Crohn's ileocolitis
Gastroenterology
(2012) - et al.
Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia
Gastroenterology
(2009) - et al.
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease
Gastroenterology
(2010) - et al.
Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
Am J Gastroenterol
(2003) - et al.
Statins and colorectal cancer
Clin Gastroenterol Hepatol
(2013) - et al.
Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases
Clin Gastroenterol Hepatol
(2015)
Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease
J Crohns Colitis
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
Mayo clinic NLP system for patient smoking status identification
J Am Med Inform Assoc
Chemoprevention of colorectal cancer in inflammatory bowel disease
Best Pract Res Clin Gastroenterol
Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study
Gastroenterology
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
Gastroenterology
Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine
Clin Gastroenterol Hepatol
Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study
Gastroenterology
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis
Gastroenterology
Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis
Clin Gastroenterol Hepatol
Colorectal cancer in patients with inflammatory bowel disease: can we predict risk?
World J Gastroenterol
Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002)
Gut
Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?
World J Gastroenterol
AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease
Gastroenterology
Review article: colorectal carcinoma and inflammatory bowel disease
Aliment Pharmacol Ther
Cited by (54)
Statin use and risk of colorectal cancer in patients with inflammatory bowel disease
2023, eClinicalMedicineColorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management
2022, GastroenterologyPrognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis
2021, GastroenterologyCitation Excerpt :Our pooled univariable analysis of 4 studies did not show a protective effect (OR, 0.71; 95% CI, 0.14-3.67). One cohort study did not report a protective effect of anti-TNF-α in a multivariable model (OR, 1.01; 95% CI, 0.62-1.65).32 One case-control study showed a protective effect of anti-TNF-α in a multivariable hazard model (HR, 0.22; 95% CI, 0.10-0.50) (Supplementary File 33A–E).33
Preventing Colitis-Associated Colon Cancer With Antioxidants: A Systematic Review
2021, Cellular and Molecular Gastroenterology and HepatologyCitation Excerpt :Other synthetic compounds such as GL-V9, a flavonoid derivative with strong antioxidant and anti-inflammatory activities, protect against tumorigenesis in a CAC model through NLRP3 inflammasome degradation.100 Statins were found to reduce CAC in IBD patients in one study101 but not in another study.102 Among natural antioxidants, vitC reduces oxidative DNA damage by neutralizing mutagenic ROS and RNI3,103 and protects from inflammation-associated tumorigenesis in different animal models of CAC.3
Associations Between Drug Exposure and Outcomes in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease
2020, Clinical Gastroenterology and HepatologyStatins and inflammatory bowel disease: Where do we stand?
2020, European Journal of Internal MedicineCitation Excerpt :Other clinical studies reported a beneficial effect of statins in patients with multiple sclerosis and systemic lupus erythematosus [61,62]. Experimental evidence shows anti-inflammatory and immunomodulatory effects of statin use, suggesting a possible role of this class of drugs in IBD and autoimmune disorders [14,63–74]. The inhibition of the mevalonate pathway causes the reduction of farnesylpyrophosphates and geranylgeranylpyrophosphates permitting the attachment of different GTPases to the cell membrane [64].
Conflicts of interest The authors disclose no conflicts.
Funding Supported by National Institutes of Health (U54-LM008748 to I.K.); the American Gastroenterological Association and the US National Institutes of Health (K23 DK097142 to A.N.A.); National Institutes of Health grant K08 AR060257 and the Harold and Duval Bowen Fund (K.P.L.); and supported by grants from the National Institutes of Health (K24 AR052403, P60 AR047782, and R01 AR049880 to E.W.K.).